ArticlePharmacoEconomics - open2026

Subcutaneous Ocrelizumab for the Treatment of Relapsing Forms of Multiple Sclerosis: A Budget Impact Model.

Camilla Porta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.